Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.59 |
| ▸ | SELP | P16109 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.50 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978433 | 1.00 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL974889 | 1.00 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL8014258 | 0.92 | PRKCA (0.54) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL4981054 | 0.90 | ENPP2 (0.60) | PRKCAPRKCEPRKCQPRKCDLPAR1 | |
| SCHEMBL4981050 | 0.90 | ENPP2 (0.60) | PRKCAPRKCEPRKCQPRKCDLPAR1 | |
| SCHEMBL9453916 | 0.88 | PRKCA (0.53) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL6346855 | 0.85 | DGKA (0.60) | PRKCEPRKCQPRKCDFAAHLPAR1 | |
| SCHEMBL6346850 | 0.85 | DGKA (0.60) | PRKCEPRKCQPRKCDFAAHLPAR1 | |
| SCHEMBL24075747 | 0.85 | PRKCA (0.80) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL1898251 | 0.85 | PRKCA (0.80) | PRKCAPRKCEPRKCQPRKCDSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868196-B2 | Preparation of glycerol derivatives and intermediates therefor | ENZYCHEM CO., LTD. (KR) | 2011-01-11 | — | — | US | disclosed |
| EP-1907345-B1 | PREPARATION OF GLYCEROL DERIVATIVES AND INTERMEDIATES THEREFOR | ENZYCHEM CO LTD (KR) | 2009-10-21 | — | — | EP | disclosed |
| US-20090253923-A1 | Preparation of glycerol derivatives ad intermediates therefor | ENZYCHEM CO., LTD. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253923-A1 | Preparation of glycerol derivatives ad intermediates therefor | FAR1, GK, AGPAT2 | PRKCA 1507/4885PRKCE 1931/4885PRKCQ 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.